

Jon M Wigginton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10764562/publications.pdf>

Version: 2024-02-01

30
papers

26,754
citations

279798

23
h-index

526287

27
g-index

30
all docs

30
docs citations

30
times ranked

29482
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 2443-2454.	27.0	10,727
2	Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 2455-2465.	27.0	6,820
3	Nivolumab plus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2013, 369, 122-133.	27.0	3,776
4	Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2014, 32, 1020-1030.	1.6	2,015
5	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558,) Tj ETQq1 1 0.784314 rgB / <i>Clinical Oncology</i> , 2015, 33, 2004-2012.	1.6	1,035
6	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2015, 33, 2013-2020.	1.6	385
7	Combination immunotherapy: a road map. , 2017, 5, 16.		325
8	Immunotherapy of cancer by IL-12-based cytokine combinations. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1705-1721.	3.1	191
9	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. , 2017, 5, 44.		181
10	IL-27 Mediates Complete Regression of Orthotopic Primary and Metastatic Murine Neuroblastoma Tumors: Role for CD8+ T Cells. <i>Journal of Immunology</i> , 2004, 173, 7170-7182.	0.8	151
11	Defining the critical hurdles in cancer immunotherapy. <i>Journal of Translational Medicine</i> , 2011, 9, 214.	4.4	139
12	Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. <i>Immunology</i> , 2011, 132, 226-239.	4.4	111
13	IFN- γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. <i>Journal of Clinical Investigation</i> , 2001, 108, 51-62.	8.2	110
14	Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. <i>Clinical Cancer Research</i> , 2011, 17, 3064-3076.	7.0	108
15	Synergistic Anti-Tumor Responses After Administration of Agonistic Antibodies to CD40 and IL-2: Coordination of Dendritic and CD8+ Cell Responses. <i>Journal of Immunology</i> , 2003, 170, 2727-2733.	0.8	105
16	Immunologic and Therapeutic Synergy of IL-27 and IL-2: Enhancement of T Cell Sensitization, Tumor-Specific CTL Reactivity and Complete Regression of Disseminated Neuroblastoma Metastases in the Liver and Bone Marrow. <i>Journal of Immunology</i> , 2009, 182, 4328-4338.	0.8	90
17	Antitumor activity of interleukin 12 in preclinical models. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 38, S16-S21.	2.3	77
18	IFN- γ -Dependent Delay of In Vivo Tumor Progression by Fas Overexpression on Murine Renal Cancer Cells. <i>Journal of Immunology</i> , 2000, 164, 231-239.	0.8	69

#	ARTICLE	IF	CITATIONS
19	Synergistic Engagement of an Ineffective Endogenous Anti-Tumor Immune Response and Induction of IFN- γ and Fas-Ligand-Dependent Tumor Eradication by Combined Administration of IL-18 and IL-2. <i>Journal of Immunology</i> , 2002, 169, 4467-4474.	0.8	66
20	Complete Regression of Established Spontaneous Mammary Carcinoma and the Therapeutic Prevention of Genetically Programmed Neoplastic Transition by IL-12/Pulse IL-2: Induction of Local T Cell Infiltration, Fas/Fas Ligand Gene Expression, and Mammary Epithelial Apoptosis. <i>Journal of Immunology</i> , 2001, 166, 1156-1168.	0.8	48
21	IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside. <i>Expert Opinion on Biological Therapy</i> , 2002, 2, 513-524.	3.1	43
22	Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).. <i>Journal of Clinical Oncology</i> , 2013, 31, CRA9006-CRA9006.	1.6	41
23	Primary Hepatocytes from Mice Treated with IL-2/IL-12 Produce T Cell Chemoattractant Activity that Is Dependent on Monokine Induced by IFN- γ (Mig) and Chemokine Responsive to γ -2 (Crg-2). <i>Journal of Immunology</i> , 2001, 166, 3763-3770.	0.8	33
24	Proteasome Inhibition to Maximize the Apoptotic Potential of Cytokine Therapy for Murine Neuroblastoma Tumors. <i>Journal of Immunology</i> , 2006, 176, 6302-6312.	0.8	32
25	Interleukin-12: Murine Models of a Potent Antitumor Agent. <i>Annals of the New York Academy of Sciences</i> , 1996, 795, 266-274.	3.8	26
26	Therapeutic Modulation of Akt Activity and Antitumor Efficacy of Interleukin-12 Against Orthotopic Murine Neuroblastoma. <i>Journal of the National Cancer Institute</i> , 2006, 98, 190-202.	6.3	13
27	The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting. , 2017, 5, .		11
28	Evaluation of the Antitumor Activity of the Interleukin-12/Pulse Interleukin-2 Combination. <i>Annals of the New York Academy of Sciences</i> , 1996, 795, 434-439.	3.8	9
29	High-Throughput Molecular and Histopathologic Profiling of Tumor Tissue in a Novel Transplantable Model of Murine Neuroblastoma: New Tools for Pediatric Drug Discovery. <i>Cancer Investigation</i> , 2012, 30, 343-363.	1.3	9
30	Multicolor Fluorescence-Based Approaches for Imaging Cytokine-Induced Alterations in the Neovascularization, Growth, Metastasis, and Apoptosis of Murine Neuroblastoma Tumors. <i>Journal of Immunotherapy</i> , 2006, 29, 151-164.	2.4	8